The global burden of lung cancer: current status and future trends
A Leiter, RR Veluswamy, JP Wisnivesky - Nature reviews Clinical …, 2023 - nature.com
Lung cancer is the leading cause of cancer-related death worldwide. However, lung cancer
incidence and mortality rates differ substantially across the world, reflecting varying patterns …
incidence and mortality rates differ substantially across the world, reflecting varying patterns …
EGFR in cancer: Signaling mechanisms, drugs, and acquired resistance
ML Uribe, I Marrocco, Y Yarden - Cancers, 2021 - mdpi.com
Simple Summary Growth factors are hormone-like molecules able to promote division and
migration of normal cells, but cancer captured the underlying mechanisms to unleash tumor …
migration of normal cells, but cancer captured the underlying mechanisms to unleash tumor …
Machine learning for genetics-based classification and treatment response prediction in cancer of unknown primary
Cancer of unknown primary (CUP) is a type of cancer that cannot be traced back to its
primary site and accounts for 3–5% of all cancers. Established targeted therapies are …
primary site and accounts for 3–5% of all cancers. Established targeted therapies are …
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer
PA Jänne, C Baik, WC Su, ML Johnson, H Hayashi… - Cancer discovery, 2022 - AACR
Receptor tyrosine-protein kinase ERBB3 (HER3) is expressed in most EGFR-mutated lung
cancers but is not a known mechanism of resistance to EGFR inhibitors. HER3-DXd is an …
cancers but is not a known mechanism of resistance to EGFR inhibitors. HER3-DXd is an …
Adenocarcinoma spectrum lesions of the lung: Detection, pathology and treatment strategies
L Succony, DM Rassl, AP Barker, FM McCaughan… - Cancer treatment …, 2021 - Elsevier
Adenocarcinoma has become the most prevalent lung cancer sub-type and its frequency is
increasing. The earliest stages in the development of lung adenocarcinomas are visible …
increasing. The earliest stages in the development of lung adenocarcinomas are visible …
[HTML][HTML] Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
JC Soria, Y Ohe, J Vansteenkiste… - New England journal …, 2018 - Mass Medical Soc
Background Osimertinib is an oral, third-generation, irreversible epidermal growth factor
receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI …
receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI …
Discovery of BLU-945, a reversible, potent, and wild-type-sparing next-generation EGFR mutant inhibitor for treatment-resistant non-small-cell lung cancer
MS Eno, JD Brubaker, JE Campbell… - Journal of medicinal …, 2022 - ACS Publications
While epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have
changed the treatment landscape for EGFR mutant (L858R and ex19del)-driven non-small …
changed the treatment landscape for EGFR mutant (L858R and ex19del)-driven non-small …
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
Background Immune checkpoint inhibitors are a new standard of care for patients with
advanced non-small-cell lung cancer (NSCLC) without EGFR tyrosine kinase or anaplastic …
advanced non-small-cell lung cancer (NSCLC) without EGFR tyrosine kinase or anaplastic …
Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer
F Gonzalvez, S Vincent, TE Baker, AE Gould, S Li… - Cancer Discovery, 2021 - AACR
Most EGFR exon 20 insertion (EGFR ex20ins) driver mutations in non–small cell lung
cancer (NSCLC) are insensitive to approved EGFR tyrosine kinase inhibitors (TKI). To …
cancer (NSCLC) are insensitive to approved EGFR tyrosine kinase inhibitors (TKI). To …
[HTML][HTML] Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase III …
Introduction Data on immuno-oncology agents in Chinese patients are limited despite a
need for new therapies. We evaluated the efficacy and safety of nivolumab in a …
need for new therapies. We evaluated the efficacy and safety of nivolumab in a …